Connor, Clark & Lunn Investment Management (CC&L)’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $214K | Sell |
|
|||||
|
2025
Q1 | $1.63M | Buy |
|
|||||
|
2024
Q4 | $1.14M | Sell |
|
|||||
|
2024
Q3 | $4.18M | Sell |
|
|||||
|
2024
Q2 | $6.69M | Buy |
|
|||||
|
2024
Q1 | $7.26M | Buy |
|
|||||
|
2023
Q4 | $4.13M | Sell |
|
|||||
|
2023
Q3 | $6.5M | Sell |
|
|||||
|
2023
Q2 | $9.5M | Sell |
|
|||||
|
2023
Q1 | $8.34M | Sell |
|
|||||
|
2022
Q4 | $10.7M | Buy |
|
|||||
|
2022
Q3 | $7.8M | Buy |
|
|||||
|
2022
Q2 | $1.94M | Buy |
|
|||||
|
2021
Q3 | – | Sell |
|
|||||
|
2021
Q2 | $225K | Sell |
|
|||||
|
2021
Q1 | $1.76M | Buy |
|
|||||
|
2020
Q4 | $364K | Buy |
|
|||||
|
2015
Q3 | – | Sell |
|
|||||
|
2015
Q2 | $389K | Sell |
|
|||||
|
2015
Q1 | $329K | Buy |
|